The VEGF family in cancer and antibody-based strategies for their inhibition

Laura A. Sullivan, Rolf A. Brekken

Research output: Contribution to journalReview articlepeer-review

142 Scopus citations


Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
Issue number2
StatePublished - Mar 2010


  • Antibodies
  • Cancer therapy
  • VEGF
  • VEGF receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The VEGF family in cancer and antibody-based strategies for their inhibition'. Together they form a unique fingerprint.

Cite this